Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 249-253

  Golubkov, Vladislav ^a,b   Garcia, Agustin ^a,c   Markland, Francis S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BURNHAM INSTITUTE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

4 HPR; Actin cytoskeleton; Angiogenesis; Endothelial cells; FAK; Fenretinide; HUVEC; Ovarian cancer; OVCAR 5

Indexed keywords

ACTIN; FENRETINIDE; FOCAL ADHESION KINASE; RETINOID;

ANGIOGENESIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; OVARY CANCER; PRIORITY JOURNAL;

ACTINS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETON; ENDOTHELIAL CELLS; FEMALE; FENRETINIDE; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; UMBILICAL VEINS;

EID: 16344363040     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Thomas A, Murray T and Thun M: Cancer statistics, 2002. CA Cancer J Clin 52: 23-47, 2002.
2. Sporn MB and Roberts AB: Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 73: 1381-1387, 1984.
3. Smith MA, Parkinson DR, Cheson BD and Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992.
4. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
5. Soprano DR, Chen LX, Wu S, Donigan AM, Borghaei RC and Soprano KJ: Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition. Oncogene 12: 577-584, 1996.
6. Sabichi AL, Hendricks DT, Bober MA and Birrer MJ: Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 90: 597-605, 1998.
7. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C and Montaldo PG: Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 55: 853-861, 1995.
8. Abulafia O, Triest WE and Sherer DM: Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72: 220-231, 1999.
9. Barcz E, Sommer E, Sokolnicka I, Gawrychowski K, Roszkowska-Purska K, Janik P and Skopinska-Rozewska E: The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells. Oncol Rep 5: 517-520, 1998.
10. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF and Brown LF: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105-1115, 1996.
11. Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, Montaldo PG, De Falco G, Caruso A, Vacca A and Ponzoni M: Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 94: 314-321, 2001.
12. Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S and Millard M: Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem 277: 49531-49537, 2002.
13. Lingen MW, Polverini PJ and Bouck NP: Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 74: 476-483, 1996.
14. Majewski S, Marczak M, Szmurlo A, Jablonska S and Bollag W: Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett 89: 117-124, 1995.
15. Supino R, Crosti M, Clerici M, Warlters A, Cleris L, Zunino F and Formelli F: Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 65: 491-497, 1996.
16. Nomizu M, Kim WH, Yamamura K, Utani A, Song SY, Otaka A, Roller PP, Kleinman HK and Yamada Y: Identification of cell binding sites in the laminin alpha 1 chain carboxyl-terminal globular domain by systematic screening of synthetic peptides. J Biol Chem 270: 20583-20590, 1995.
17. Repesh LA: A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9: 192-208, 1989.
18. Markland FS, Shieh K, Zhou Q, Golubkov V, Sherwin RP, Richters V and Sposto R: A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis 31: 183-191, 2001.
19. Wu S, Zhang ZP, Zhang D, Soprano DR and Soprano KJ: Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all- trans-retinoic acid. Exp Cell Res 257: 118-126, 1997.
20. Wu JM, DiPietrantonio AM and Hsieh TC: Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 6: 377-388, 2001.
21. Turner CE: Paxillin and focal adhesion signalling. Nat Cell Biol 2: E231-236, 2000.
22. Sieg DJ, Hauck CR and Schlaepfer DD: Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci 112: 2677-2691, 1999.
23. Webb DJ, Parsons JT and Horwitz AF: Adhesion assembly, disassembly and turnover in migrating cells - over and over and over again. Nat Cell Biol 4: E97-100, 2002.
24. Dipietrantonio A, Hsieh TC and Wu JM: Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem Biophys Res Commun 224: 837-842, 1996.
25. Vaccari M, Silingardi P, Argnani A, Horn W, Giungi M, Mascolo MG, Grilli S and Colacci A: In vitro effects of fenretinide on cell-matrix interactions. Anticancer Res 20: 3059-3066, 2000.
26. Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A and Iwaguchi T: A highly potent antiangiogenic activity of retinoids. Cancer Lett 48: 157-162, 1989.
27. Pienta KJ, Nguyen NM and Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 53: 224-226, 1993.
28. Lansink M, Koolwijk P, van Hinsbergh V and Kooistra T: Effect of steroid hormones and retinoids on the formation of capillary- like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression. Blood 92: 927-938, 1998.
29. Matsumura T, Wolff K and Petzelbauer P: Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol 158: 3408-3416, 1997.
30. Lichtenbeld HH, van Dam-Mieras MC and Hillen HF: Tumour angiogenesis: pathophysiology and clinical significance. Neth J Med 49: 42-51, 1996.